Danaher Corporation (DHR) Stock Analysis
$DHR · Healthcare · Medical - Diagnostics & Research · NYSE
Danaher (DHR), a Medical - Diagnostics & Research company, is listed on NYSE, has a market capitalization of about $161.46B and trades at 37.7x trailing earnings.
Price
$229.68
Market cap
$161.46B
P/E ratio
37.7x
Dividend yield
0.63%
About Danaher Corporation
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, se
How StockWorthy values DHR
StockWorthy forecasts Danaher Corporation's revenue, operating profitability, reinvestment (capital expenditure, depreciation and working capital) and unlevered free cash flow, then discounts those cash flows using a normalized cost of capital built from DHR's size, profitability and balance-sheet risk. Terminal growth is adjusted to reflect the company's mature growth profile rather than a fixed number. The model presents bear, base and bull scenarios, and every key assumption stays transparent and adjustable in the full StockWorthy analysis. Results are educational and not investment advice.
Related stocks
See DHR's Fair Value
Create a free account to view Danaher Corporation's base-case fair value, the bear–bull modeled range, and every assumption behind them. Free accounts include 5 stock valuations per month — plus Advanced DCF models, financial charts, dividends, and peer analysis.